Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Evaluate CAPecitabine Plus Pembrolizumab as Post-operative Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Chemo-immunotherapy

Next Previous
Trial Profile

A Phase II Study to Evaluate CAPecitabine Plus Pembrolizumab as Post-operative Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Chemo-immunotherapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Pembrolizumab (Primary)
  • Indications Male breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms CAPPA

Most Recent Events

  • 13 Mar 2025 Planned End Date changed from 1 Jun 2028 to 1 Aug 2028.
  • 13 Mar 2025 Planned primary completion date changed from 1 Jun 2028 to 1 Aug 2028.
  • 13 Mar 2025 Planned initiation date changed from 1 Jan 2025 to 20 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top